Search Results
Your search for The ASCO matches 21454 pages
Showing 15851 - 15900ASCO’s Incoming President-Elect Charts His Course for 2017
Bruce E. Johnson, MD, FASCO, was elected ASCO President for the 2017–2018 term this past December and will take office as President-Elect during the ASCO Annual Meeting, June 3–7, 2016, in Chicago. As an ASCO member since 1986, Dr. Johnson brings over 30 years of experience with ASCO to the...
PET Scan Use in Follow-up Care for Lung and Esophageal Cancer Shows Wide Variation Between Hospitals, No Impact on Survival
A new study suggests that one approach to watching for a cancer's return is being inappropriately used at many hospitals and isn't helping patients survive longer. The findings are published by Healy et al in the Journal of the National Cancer Institute. The study looked at how often survivors ...
Two Forms of Radiosurgery for Brain Metastases Are Equally Effective
While two advanced radiosurgery approaches—Gamma Knife and RapidArc—offer different strengths, they are equally effective at eradicating cancer in the brain, say researchers at Sidney Kimmel Cancer Center at Jefferson. Their study, published by Liu et al in Frontiers in Oncology,...
Half of Elderly Patients With Colorectal Cancer Receive Expensive Therapy With Little Survival Benefit
A study published by Bradley et al in Medical Care showed that over a recent 10-year period, the rate of metastatic colorectal cancer patients older than age 75 receiving three or more treatments increased from 2% to 53%. During this period, 1-year treatment costs increased 32% to reach an...
Children With Leukemia From High-Poverty Areas More Likely to Suffer Early Relapse
Among children with acute lymphoblastic leukemia (ALL), the most common pediatric cancer, those who live in high-poverty areas are substantially more likely to suffer early relapse than other patients, despite having received the same treatment, according to new research from Dana-Farber/Boston...
Mylin A. Torres, MD, Named Director of Winship’s Glenn Family Breast Center
Winship Cancer Institute of Emory University has named Mylin A. Torres, MD, the new Director of the Glenn Family Breast Center, effective January 19, 2016. She succeeds Ruth O’Regan, MD, who now heads the University of Wisconsin Division of Hematology and Oncology. Dr. Torres is Associate Professor ...
Hidayatullah G. Munshi, MD, Named Program Leader of Tumor Environment and Metastasis Program at Robert H. Lurie Comprehensive Cancer Center
Hidayatullah G. Munshi, MD, has been named Leader of the Tumor Environment and Metastasis (TEAM) Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. The TEAM Program utilizes an integrative approach to elucidate key molecular interactions between tumor cells and...
Marc S. Ernstoff, MD, Named UB Chief of Hematology/Oncology, Roswell Park Chair of Medicine
Marc S. Ernstoff, MD, has been appointed Professor and Chief of the Division of Hematology/Oncology in the Department of Medicine in the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo (UB) and Chair of the Department of Medicine and Senior Vice President of Clinical...
Expert Point of View: Irvin M. Modlin, MD, Lisa Bodei, MD, and Eric Liu, MD
The ASCO Post interviewed Irvin M. Modlin, MD, Emeritus Professor of Gastroenterological Surgery, Yale University School of Medicine, regarding his thoughts on the NETTER-1 results and peptide receptor radionuclide therapies for neuroendocrine tumors. Dr. Modlin led the first study of a peptide...
Radiolabeled Somatostatin Analog May Represent A Paradigm Change in the Treatment of Neuroendocrine Tumors
A radiolabeled somatostatin analog compound, 177Lu-DOTA0-Tyr3-Octreotate (Lu-177 dotatate), reduced the risk of disease progression or death by 79% in the international phase III NETTER-1 population of previously treated, advanced neuroendocrine tumors of midgut origin.1 Lu-177 dotatate belongs to...
ASCO Provides Support and Guidance for the White House Cancer Moonshot Initiative
Although President Richard Nixon signed the National Cancer Act in 1971, essentially declaring a war on cancer, the genesis of the idea had actually been born 2 years earlier, after the first landing on the moon set off a new era of scientific exploration and sparked a belief that any scientific...
Expert Point of View: Irvin M. Modlin, MD, and Eric Liu, MD
Two neuroendocrine tumor experts had slightly different reactions to the latest RADIANT-4 data. Irvin M. Modlin, MD, Emeritus Professor of Gastroenterological Surgery at Yale University School of Medicine, New Haven, Connecticut, said in an interview that he essentially restricts his use of...
Everolimus Effective in Neuroendocrine Tumors of Gastrointestinal Origin
In a subgroup analysis of the phase III RADIANT-4 trial, focusing on neuroendocrine tumors of gastrointestinal origin, the mTOR inhibitor everolimus (Afinitor) essentially doubled the median progression-free survival time, compared with placebo, researchers reported at the 2016 Gastrointestinal...
Adding Immunotherapy to Radiofrequency Ablation in Colorectal Cancer With Liver Metastasis Shows Promise in Preclinical Models
In a retrospective case-controlled study conducted in patients with colorectal cancer who had received primary tumor resection with or without preoperative radiofrequency ablation for liver metastases, the electrical procedure was found to induce antitumor immune responses in the...
Study Links Normal Stem Cells to Aggressive Prostate Cancer
A study that revealed new findings about prostate cells may point to future strategies for treating aggressive and therapy-resistant forms of prostate cancer. The study proved that the prostate basal cell layer contains adult stem cells, which possess a unique gene-expression profile resembling the ...
New Biomarker Identifies Uveal Melanoma Patients at High Risk for Metastasis
Among uveal melanomas categorized as class 1, those with high levels of PRAME mRNA were more likely to metastasize than those with low levels of PRAME mRNA, suggesting that patients who have class 1 uveal melanoma with high levels of PRAME mRNA should be monitored more closely for metastatic...
Metabolic Phenotyping of Blood Plasma Allows for the Detection of Lung Cancer
Metabolic phenotyping of blood plasma by proton nuclear magnetic resonance (H-NMR) identified unique metabolic biomarkers specific to lung cancer patients and allowed for the accurate identification of a cohort of patients with early and late-stage lung cancer. These findings were published by...
SSO 2016: Federal 'Moonshot' Fight Against Cancer Means More Resources for Surgical Oncology Professionals
The 69th Society of Surgical Oncology (SSO) Annual Cancer Symposium, being held March 2–5 in Boston, will include featured lecturers with ties to the recently announced White House “moonshot” initiative to cure cancer—a proposed $1 billion in spending on cancer research over ...
Light Reflectance Technique May Improve Ability to Remove Prostate Cancer During Surgery
Researchers at UT Southwestern Medical Center have determined that light reflectance spectroscopy can differentiate between malignant and benign prostate tissue with 85% accuracy, a finding that may lead to real-time tissue analysis during prostate cancer surgery. These findings were reported...
Breast Reconstruction Using Abdominal Tissue: Differences in Outcome With Four Techniques
In women undergoing breast reconstruction using autologous tissue, newer muscle-sparing abdominal flaps can reduce complications while improving some aspects of quality of life, according to a study by Macadem et al in Plastic and Reconstructive Surgery. Comparison of four types of abdominal flaps ...
Study Finds 36% Increase in Number of Male Smokers in India Over 17 Years
The number of men smoking tobacco in India rose by more than one third to 108 million between 1998 and 2015, according to a new study published in the journal BMJ Global Health. The study also found that cigarettes were replacing the traditional bidi, a small, inexpensive Indian cigarette,...
Malignant Brain Tumors Most Common Cause of Cancer Deaths in Adolescents and Young Adults
A new report published by Ostrom et al in the journal Neuro-Oncology sponsored by the American Brain Tumor Association (ABTA) found that malignant brain tumors are the most common cause of cancer-related deaths in adolescents and young adults aged 15 to 39, and the most common cancer occurring...
Steven Shak, MD, on Breast Cancer–Specific Mortality
Steven Shak, MD, of Genomic Health, discusses mortality among patients with early-stage hormone receptor–positive invasive breast cancer in the SEER database who were treated based on the 21-gene Recurrence Score results (Abstract 176).
Ethan Basch, MD, on Assessing Quality: Patient-Reported Data
Ethan Basch, MD, of the University of North Carolina at Chapel Hill, summarizes a session he chaired on the burgeoning use of patient-reported outcomes and wearable sensors in clinical practice and research.
Monika K. Krzyzanowska, MD, MPH, on Patient-Centered Outcomes Research: Expert Perspective
Monika K. Krzyzanowska, MD, of Princess Margaret Cancer Centre, summarizes a session that she co-chaired on this key topic.
Randall F. Holcombe, MD, on Delivering Quality Care in a Large, Urban Institution
Randall F. Holcombe, MD, of the Icahn Mount Sinai School of Medicine, discusses the challenges of delivering quality care in an academic setting at a large hospital.
Lee N. Newcomer, MD, on Assessing Quality: Payer Perspective
Lee N. Newcomer, MD, of the UnitedHealth Group, gives his perspective on how to assess quality in the age of precision medicine.
Robert Miller, MD: CancerLinQ Update
Robert Miller, MD, ASCO’S Vice President of Quality and Guidelines, discusses CancerLinQ, the “big data” technology platform, and implementation of a rapid learning system for oncology based on Institute of Medicine principles.
Allison Kurian, MD, on Assessing Quality in the Age of Precision Medicine
Allison Kurian, MD, of Stanford University School of Medicine, discusses pressing questions about the clinical utility and value of extended genomic testing and other forms of precision medicine.
Joseph O. Jacobson, MD, on Improving Cancer Care: What Works, What Doesn’t, and Why
Joseph O. Jacobson, MD, of the Dana-Farber Cancer Institute, discusses a session he co-chaired on the thorny questions of how best to improve cancer care.
Sandra L. Wong, MD's, Oral Abstract Discussion: Expert Perspective
Sandra L. Wong, MD, of the Dartmouth-Hitchcock Medical Center, summarizes three abstracts for which she was the discussant. The topics were rates of surgical site infections, an online resource for hospital cancer surgery volumes, and barriers to oncology appointments at comprehensive cancer...
Lawrence N. Shulman, MD, on Survival as a Measure of Quality and Advances in Therapy
Lawrence N. Shulman, MD, of the University of Pennsylvania, discusses his paper, which explores lessons learned from analyses of the National Cancer Data Base. (Abstract 173)
Patricia A. Ganz, MD, on Improving Quality and Value in Cancer Care
Patricia A. Ganz, MD, of the University of California at Los Angeles, the 2016 winner of the Joseph V. Simone Award, summarizes her “Lecture for Excellence in Quality and Safety in the Care of Patients With Cancer.”
Sarina Isenberg, PhD Candidate, on Better Care at a Better Cost
Sarina Isenberg, PhD Candidate, of the Johns Hopkins Bloomberg School of Public Health, discusses the cost savings of a comprehensive hospital-based palliative care program. (Abstract 2)
Joseph V. Simone, MD, on Safety and Quality in Cancer Care: The Big Picture
Joseph V. Simone, MD, of the Simone Consulting Company, reflects on the prospects for the future of safety and quality.
Craig Earle, MD, on The Science of Quality
Craig Earle, MD, of Canada’s Institute for Clinical Evaluative Sciences, summarizes abstracts discussed in a ticketed session that he co-chaired on this key topic. (Abstracts 173, 174, 175)
Kerin B. Adelson, MD, on Improving Cancer Staging
Kerin B. Adelson, MD, of the Yale Cancer Center, discusses an electronic decision support tool to capture staging data. This information allows automated reports for clinical trial screening, outcomes analysis, quality comparisons, and reporting. (Abstract 151)
Kerin B. Adelson, MD, on Improving End-of-Life Planning and Reducing Futile Care
Kerin B. Adelson, MD, of the Yale Cancer Center, discusses the major healthcare cost drivers at the end of life—aggressive treatments, emergency room visits, and futile care—and strategies for improving value. (Abstract 3)
Dawn L. Hershman, MD, on Improving Quality and Safety With Multidisciplinary Teams
Dawn L. Hershman, MD, of Columbia University Medical Center, summarizes a joint ASCO/NCI session on this important topic, including the challenges and solutions.
2016 Quality Care Symposium: New Triage System Decreases Emergency Room Visits by Oncology Patients in Florida
A quality improvement initiative to reduce patients’ reliance on emergency room (ER) visits to treat cancer treatment side effects has shown to be highly effective, according to early findings from a new study. The strategy, involving a telephone triage service coupled with patient education, ...
2016 Quality Care Symposium: Online Tool Improves Access to Information on Cancer Treatment Costs
To facilitate doctor/patient conversations about costs of cancer care, researchers developed and piloted an online tool for oncologists. The innovative resource lists prices for the 50 most commonly prescribed cancer treatment regimens. A survey of the pilot users at four clinics in Washington...
2016 Quality Care Symposium: Study Suggests Many Women With Early Breast Cancer Receive Unnecessary Imaging Tests
A new study suggests that up to 60% of the computed tomography (CT) scans, bone scans, and positron-emission tomography (PET) scans performed for more than 29,000 Michigan women diagnosed with early breast cancer between 2008 and 2014 could not be medically justified based on retrospective record...
FDA Approves Everolimus for Neuroendocrine Tumors of Gastrointestinal or Lung Origin
The U.S. Food and Drug Administration today approved everolimus (Afinitor) for the treatment of adult patients with progressive, well-differentiated nonfunctional neuroendocrine tumors of gastrointestinal or lung origin with unresectable, locally advanced, or metastatic disease. ...
FDA Approves Obinutuzumab in Follicular Lymphoma
The U.S. Food and Drug Administration (FDA) today approved obinutuzumab (Gazyva) for use in combination with bendamustine (Bendeka, Treanda) followed by obinutuzumab monotherapy for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab...
Cancer Statistics for African Americans, 2016
A new report outlines substantial progress in reducing the mortality gap between blacks and whites for some cancers, while the gap has widened or remained level for two leading cancers: breast cancer in women and colorectal cancer in men. The findings are included in Cancer Statistics for African...
Weight and Height During Adolescence May Impact Future Risk of Developing Non-Hodgkin Lymphoma
A new analysis indicates that higher body weight and taller stature during adolescence increase the risk of developing Non-Hodgkin lymphoma (NHL). The findings were published by Leiba et al in Cancer. Rates of NHL have increased worldwide, and research suggests that rising rates of obesity may be...
Quality Improvement Projects Aim at Reducing Errors in Prescribing IV and Oral Chemotherapy
Two quality improvement projects described in the Journal of Oncology Practice resulted in reduced errors in prescribing intravenous (IV) and oral chemotherapy. A project at the University of Texas Medical Branch in Galveston outpatient infusion centers first identified 15 different types of...
ASCO Commends Confirmation of Robert M. Califf, MD, as FDA Commissioner
“We commend the U.S. Senate for confirming Robert M. Califf, MD, as Commissioner of the Food and Drug Administration (FDA). Dr. Califf brings extraordinary expertise and vision to this position and we are confident that his appointment will positively impact cancer care. “Dr. Califf's...
Eye Movement Affected in Some Former Childhood Cancer Patients
A study from Lund University in Sweden has shown that commonly used chemotherapy toxins impair the eyesight in childhood cancer survivors in a way that indicates an impact on the central nervous system. The results were published by Einarsson et al in PLOS One. It was not the former patients' ...
First-in-Class Drug ONC201 Shows Potential for Some Blood Cancers
ONC201, an investigational anticancer drug that triggers cell death in various tumor types, may have clinical potential for some blood cancers including mantle cell lymphoma and acute myeloid leukemia (AML), according to a recent clinical study. A research team led by Michael Andreeff, MD, PhD,...
